US Pharma MarketingTwo House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
China’s clinical trial boom under scrutiny after 3 deaths come to light
Two House Republicans are asking the FDA to increase oversight of China-generated clinical data after three trial deaths are reported.
Source: PharmaVoice